DK1095059T3 - Kemotaksi-hæmmende protein af staphylococcus (chips) og dets anvendelse - Google Patents

Kemotaksi-hæmmende protein af staphylococcus (chips) og dets anvendelse

Info

Publication number
DK1095059T3
DK1095059T3 DK99933284T DK99933284T DK1095059T3 DK 1095059 T3 DK1095059 T3 DK 1095059T3 DK 99933284 T DK99933284 T DK 99933284T DK 99933284 T DK99933284 T DK 99933284T DK 1095059 T3 DK1095059 T3 DK 1095059T3
Authority
DK
Denmark
Prior art keywords
chips
staphylococcus
chemotaxia
inhibitory protein
treatment
Prior art date
Application number
DK99933284T
Other languages
Danish (da)
English (en)
Inventor
Strijp Johannes Antonius G Van
Kessel Cornelis Petrus Mar Van
Original Assignee
Alligator Bioscience Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience Ab Publ filed Critical Alligator Bioscience Ab Publ
Application granted granted Critical
Publication of DK1095059T3 publication Critical patent/DK1095059T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK99933284T 1998-07-10 1999-07-12 Kemotaksi-hæmmende protein af staphylococcus (chips) og dets anvendelse DK1095059T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL1009614 1998-07-10

Publications (1)

Publication Number Publication Date
DK1095059T3 true DK1095059T3 (da) 2006-10-02

Family

ID=19767471

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99933284T DK1095059T3 (da) 1998-07-10 1999-07-12 Kemotaksi-hæmmende protein af staphylococcus (chips) og dets anvendelse

Country Status (22)

Country Link
US (2) US20050143307A1 (de)
EP (1) EP1095059B1 (de)
JP (1) JP2002520336A (de)
KR (1) KR20010053290A (de)
CN (1) CN1309662A (de)
AT (1) ATE328898T1 (de)
AU (1) AU4935999A (de)
BG (1) BG105120A (de)
BR (1) BR9911944A (de)
CA (1) CA2333898A1 (de)
CY (1) CY1105343T1 (de)
DE (1) DE69931784T2 (de)
DK (1) DK1095059T3 (de)
ES (1) ES2270609T3 (de)
HU (1) HUP0102975A2 (de)
IL (1) IL140768A0 (de)
NO (1) NO20010140L (de)
NZ (1) NZ509051A (de)
PL (1) PL345452A1 (de)
PT (1) PT1095059E (de)
WO (1) WO2000002913A1 (de)
ZA (1) ZA200100092B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002520336A (ja) * 1998-07-10 2002-07-09 ヤリ・ファーマシューティカルズ・ベスローテン・フェンノートシャップ スタフィロコッカスの走化性阻害タンパク質（ｃｈｉｐｓ）およびその使用
EP1118663A1 (de) * 2000-01-07 2001-07-25 Universiteit Utrecht Nukleinsäuren kodierend für Chemotaxis-hemmende Polypeptide
US20020086292A1 (en) 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
WO2003006048A1 (en) * 2001-07-11 2003-01-23 Jari Pharmaceuticals B.V. Combination of chips (chemotaxis inhibiting protein from staphylococcus aureus)-based compounds
DK1641926T3 (da) * 2003-07-08 2011-06-27 Umc Utrecht Holding Bv Terapeutisk anvendelse af LPI, en stafylokokal lectinstiinhibitor ved inflammatoriske sygdomme
EP1586583A3 (de) * 2004-04-16 2005-11-16 Alligator Bioscience AB (publ) Substanzen die der C5a Komplementrezeptor blockieren und deren Verwendung in der Therapie
WO2006011137A2 (en) 2004-07-26 2006-02-02 State Of Israel, Department Of Agriculture, Kimron Veterinary Institute Novel bacteria and pharmaceutically active products obtained therefrom
GB2432366B (en) * 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
GB0607798D0 (en) * 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772584A (en) * 1986-05-23 1988-09-20 Cleary Paul P Inhibitor of C5a-mediated chemotaxis
AU2509592A (en) * 1991-08-22 1993-03-16 Washington University Polynucleotide probes for salmonella
US5514555A (en) * 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5514455A (en) * 1994-07-08 1996-05-07 Union Carbide Chemicals & Plastics Technology Corporation Film extruded from an in situ blend of ethylene copolymers
US5817476A (en) * 1995-06-07 1998-10-06 Genetics Institute, Inc. Polynucleotides encoding interleukin-1 receptor intracellular ligand proteins
US7153655B2 (en) * 1998-06-16 2006-12-26 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence
JP2002520336A (ja) * 1998-07-10 2002-07-09 ヤリ・ファーマシューティカルズ・ベスローテン・フェンノートシャップ スタフィロコッカスの走化性阻害タンパク質（ｃｈｉｐｓ）およびその使用
JP3722194B2 (ja) * 1999-05-20 2005-11-30 セイコーエプソン株式会社 画像表示システム
EP1118663A1 (de) * 2000-01-07 2001-07-25 Universiteit Utrecht Nukleinsäuren kodierend für Chemotaxis-hemmende Polypeptide
US6958213B2 (en) * 2000-12-12 2005-10-25 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function
US20020086292A1 (en) * 2000-12-22 2002-07-04 Shigeaki Harayama Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules
CA2485506C (en) * 2002-05-17 2012-02-28 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function

Also Published As

Publication number Publication date
US20080242605A1 (en) 2008-10-02
PL345452A1 (en) 2001-12-17
PT1095059E (pt) 2006-10-31
WO2000002913B1 (en) 2000-03-30
BG105120A (en) 2001-11-30
WO2000002913A1 (en) 2000-01-20
CN1309662A (zh) 2001-08-22
ZA200100092B (en) 2001-07-23
AU4935999A (en) 2000-02-01
HUP0102975A2 (hu) 2001-11-28
ATE328898T1 (de) 2006-06-15
EP1095059A1 (de) 2001-05-02
NZ509051A (en) 2003-01-31
NO20010140D0 (no) 2001-01-09
ES2270609T3 (es) 2007-04-01
JP2002520336A (ja) 2002-07-09
CY1105343T1 (el) 2010-03-03
IL140768A0 (en) 2002-02-10
BR9911944A (pt) 2001-09-25
DE69931784T2 (de) 2007-06-14
CA2333898A1 (en) 2000-01-20
NO20010140L (no) 2001-03-01
EP1095059B1 (de) 2006-06-07
US20050143307A1 (en) 2005-06-30
DE69931784D1 (de) 2006-07-20
KR20010053290A (ko) 2001-06-25

Similar Documents

Publication Publication Date Title
NO20051082L (no) Antimikrobielle kinoloner, deres sammensetninger og anvendelser
EA200301115A1 (ru) Кристаллические формы азитромицина
SE0102315D0 (sv) Compounds
WO2003005999A3 (en) Methods of treating cytokine mediated diseases
GB0125222D0 (en) Composition for the treatment of microbial infections
BR0014470A (pt) Inibidores de fab i
CY1106958T1 (el) Ν-αλκυλο-4-μεθυλεναμινο-3-υδροξυ-2-πυριδονες ως αντιμικροβιακα
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
NO20052362D0 (no) Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner
ATE267830T1 (de) Als cox-hemmer verwendbare sulfonylphenylpyrazol- verbindungen
NO992492L (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
TR200003170T2 (tr) MRS inhibitörleri ve bakterisid olarak kullanılan quinolone'lar
CY1105343T1 (el) Σταφυλοκοκκικη πρωτεϊνη αναστολης του χημειοτακτισμου (chips) και η χρηση αυτης
DE60042401D1 (de) Fab-i inhibitoren
NZ510369A (en) Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
DE60310767D1 (de) PYRAZOL-3,4-d-PYRIMIDINDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON H.PYLORI-INFEKTIONEN
YU102503A (sh) Kondenzovani pirimidinski dhfr inhibitori kao antibakterijska sredstva
DE60105614D1 (de) Oxazinochinolone für die behandlung viraler infektionen
TNSN06453A1 (en) Treatment of bacterial infections
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
AU2003210850A1 (en) N-substituted3-hydroxy-4-pyridinones and pharmaceuticals containing thereof
PT1358182E (pt) Derivados de diazocinas e sua utilizacao como inibidores de triptase
SE0002045D0 (sv) New use
DE60324466D1 (de) Zusammensetzungfür die behandlung von mycobakterieninfektionen